Evidence map›Paper›PMID 33442678›Full record

ArticleResearch square2021

A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques.

Gary Baisa, David Rancour, Keith Mansfield, Monika Burns, Lori Martin, Daise Cunha, Jessica Fischer, Frauke Muecksch, Theodora Hatziioannou, Paul D Bieniasz and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 2 countries.

Gary BaisaIntuitive Biosciences.
David RancourLytic Solutions.
Keith MansfieldNovartis Institutes for BioMedical Research Inc.
Monika BurnsNovartis Institutes for BioMedical Research Inc.
Lori MartinNovartis Institutes for BioMedical Research Inc.
Daise CunhaCovance Greenfield Laboratories.
Jessica FischerCovance Greenfield Laboratories.
Frauke MueckschThe Rockefeller University.
Theodora HatziioannouThe Rockefeller University.
Paul D BieniaszHoward Hughes Medical Institute.
Fritz SchomburgLytic Solutions.
Kimberly LukeIntuitive Biosciences.ORCID 0000-0002-2145-2474
Novartis (Switzerland) · CH

Funding

Overcoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS.R01AI078788 · NIAID · ROCKEFELLER UNIVERSITY · PI HATZIIOANNOU, THEODORA · 2008 to 2021
$9.3M
Discovery and Mechanism of Antiretroviral FactorsR37AI064003 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2011 to 2020
$4.9M
NIAID NIH HHS R01 AI078788NIAID NIH HHS R37 AI064003
6 · The paper itself

Abstract

Background: Vaccines that generate robust and long-lived protective immunity against SARS-CoV-2 infection are urgently required. Methods: We assessed the potential of vaccine candidates based on the SARS-CoV-2 spike in cynomolgus macaques ( Results: A robust IgG response to the spike protein was detected as early as 2 weeks after immunization with either protein and maintained for over 20 weeks. Sera from animals immunized with antigens derived from the RBD were able to prevent binding of soluble spike proteins to the ACE2 receptor, shown by Conclusions: These data support the utility of spike subunit-based antigens as a vaccine for use in humans.

Indexed as

antibodymacaqueneutralizingRBDSARS-CoV-2spikevaccine

Identifiers

PMID33442678
PMCPMC7805460
OpenAlexW3119804281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.